Walgreens Virtual Healthcare adds weight management services
Patients can access weight management care for $49 per visit, no monthly subscription needed.
GLP-1s
Kroger expands savings programs to improve access to GLP-1 medications
The initiative merges pharmacy access with nutrition support, fresh food, and dietitian services, making Kroger a comprehensive destination for weight management and wellness.
Zepbound now available in multi-dose KwikPen
Used by millions of patients worldwide, the KwikPen for single-patient use offers a new option for receiving Zepbound.
Novo Nordisk debuts Wegovy pill in first big game ad push
The spot anchors the company’s new “A New Way to Wegovy®” campaign, using humor to reshape weight management talks and challenge the idea that medication is “the easy way out.”
Publix Pharmacy provides savings on certain GLP-1 medications
Customers can consult their Publix Pharmacist for offer details, pricing, and ways to lower out-of-pocket costs for prescriptions.
BetterWay launches GLP-1 blood testing panel at Texas retail locations
Patients in Austin and Temple can now access medications and lab results in a single visit.
Lilly picks Pennsylvania for U.S. injectable manufacturing site
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide.
Ro to debut Super Bowl spot starring Serena Williams
Super Bowl ad highlights the health benefits Williams has experienced on Ro and marks the launch of a new multi-channel national campaign starring real Ro patients.
Strive sues Eli Lilly and Novo Nordisk over GLP-1 access
Strive Compounding Pharmacy accuses drugmakers of anti-competitive actions to suppress lawful compounded GLP-1 medications and restrict patient choice.
FDA approves Novo Nordisk’s oral GLP-1 pill for weight loss
The approval expands the Wegovy portfolio beyond injections, providing a new administration option for patients.
Novo Nordisk files FDA application for once-weekly obesity treatment
“The FDA submission of CagriSema marks an important milestone and signals a new era in weight management,” said Novo Nordisk CEO.
Novo Nordisk seeks FDA approval for 7.2 mg Wegovy dose
If accepted, the agency is expected to complete its review within one to two months.
retailmediaIQ hosts Re-imagining Women’s Wellness webcast
Industry leaders from NielsenIQ, WSL Strategic Retail, and Think Blue will discuss the forces driving women’s health innovation.
Novo Nordisk cuts prices on Wegovy and Ozempic
The company reduced its prices following pressure from the Trump administration, which urged the company and competitor Eli Lilly to lower the cost of widely used weight-loss and diabetes drugs.
retailmediaIQ + NIQ + Think Blue: Re-imagining Women’s Wellness webinar
Save the Date: Tuesday, November 25, 2:00 p.m. ET.
Trump strikes historic deal to cut drug prices
Prices for Wegovy, Ozempic, and Zepbound drop from over $1,000 to $350 with the new deal. Medicare coverage begins for GLP-1 obesity drugs for the first time.